AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06261268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
Study NCT04637113 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study.
Study NCT05768919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 1
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks
Study NCT05768919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 2
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
Study NCT05768919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 3
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks
Study NCT05768919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 4a
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
Study NCT05026008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375
Description: The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
Study NCT05026008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
Study NCT05139056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural Stem Cells-expressing CRAd-S-pk7
Description: Given intracerebrally
Study NCT05139056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT04620239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: padeliporfin VTP
Description: During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
Study NCT06357364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
Study NCT06357364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Starting on Time and Planning Realistically
Description: Learning of realistic planning, and timely starting of work.
Study NCT06357364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Working Time Restriction
Description: Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
Study NCT05638659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized dual-task balance and home program
Description: Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
Study NCT05638659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical consultation and traditional balance training
Description: Participants were assigned to read the health education flier and were assessed directly.
Study NCT04774926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: 120 mg/ml solution for intravitreal injection
Study NCT04792580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout.
Study NCT04792580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
Study NCT05640921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gi-CBT
Description: Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
Study NCT05640921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Orientation
Description: The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
Study NCT05107739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug Product De-TIL-0255
Description: Autologous tumor-infiltrating lymphocytes
Study NCT06480422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental breathing technique
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.
Study NCT06480422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autogenic drainage
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes.
Study NCT06480422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic drainage
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes.
Study NCT05207605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Stabilization (RS)
Description: Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
Study NCT05207605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie technique
Description: McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
Study NCT04830514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended Dietary Allowance of Protein
Description: 0.8 g/kg/day protein intake
Study NCT04830514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual protein intake
Description: 1.0 g/kg/day protein intake
Study NCT04830514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Protein Intake
Description: 1.5 g/kg/day protein intake
Study NCT06647498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug
Description: Administered subcutaneously every 12 weeks
Study NCT06647498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remternetug
Description: Administered subcutaneously every 12 weeks
Study NCT06647498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Remternetug)
Description: Administered as subcutaneous injection of placebo every 12 weeks
Study NCT05394714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magicell-NK contains NK cells suspended in 100 mL normal saline
Description: Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
Study NCT04589325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Study NCT04589325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Study NCT06064604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
Study NCT05148533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ1133 Injection
Description: TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
Study NCT06064604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Exoskeleton
Description: The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
Study NCT06064604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton
Description: The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
Study NCT05483270 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: the timing of embryo transfer in freeze-all cycles
Description: Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.
Study NCT05483270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the timing of embryo transfer in freeze-all cycles
Description: Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.
Study NCT05243641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
Study NCT05243641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib will be supplied at 200 mg and 150 mg tablets
Study NCT04824859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education Events (CME)
Description: An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial Connect Portal
Description: A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Trial Newsletters
Description: Electronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit Bias Training
Description: A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recruitment Dashboard
Description: A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio Profiler
Description: An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility Calculator
Description: A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Trial Education Sessions (Community Residents Only)
Description: An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)
Description: A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.
Study NCT06560398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Patient Information (Moffitt Patients Only)
Description: Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.
Study NCT06560398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Control group with no intervention.
Study NCT06562803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double plasma cytokine adsorption system with sequential low-dose plasma exchange
Description: Both groups received comprehensive medical treatment, including antiviral therapy for hepatitis B, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. Artificial liver therapy was initiated for both groups on the day of enrollment, with treatments administered every other day for a total of two sessions.~The experimental group underwent treatment with the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused.
Study NCT06562803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma exchange
Description: Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.
Study NCT05635851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate Only Product in Oromucosal Dose Form
Description: Glyceryl trinitrate will be administered via sublingual spray.
Study NCT05635851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual spray
Description: A placebo sublingual spray will be administered.
Study NCT06500780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and Decision Aid
Description: Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
Study NCT05630092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximal 6-minute Walk Test (Max_6MWT)
Description: Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
Study NCT05630092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Normal speed 6-minute Walk Test (Nor_6MWT)
Description: Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
Study NCT05942053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match vitamin K2 capsules once per day.
Study NCT05942053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
Study NCT05948579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B Vilazodone Hydrochloride (HCl)
Description: Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
Study NCT05948579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention B Placebo
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.